Comprehensive assessment for miRNA polymorphisms in hepatocellular cancer risk: a systematic review and meta-analysis

Wang, Ben-gang; Jiang, Li-yue; Xu, Qian

doi:10.1042/bsr20180712

Cited by 9 publications

(4 citation statements)

References 82 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, patients with CC or CG genotypes of rs2910164 were more susceptible to the other cancers. At the same time, three large meta-analyses found that the CC genotype was associated with a decreased risk of cervical, hepatocellular, and prostate cancer [ 123 , 124 , 125 ].…”

Section: Discussionmentioning

confidence: 99%

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis

et al. 2022

View full text Add to dashboard Cite

There is growing interest in single nucleotide polymorphisms (SNPs) in the genes of microRNAs (miRNAs), which could be associated with susceptibility to colorectal cancer (CRC) and therefore for prognosis of the disease and/or treatment response. Moreover, these miRNAs-SNPs could serve as new, low-invasive biomarkers for early detection of CRC. In the present article, we performed a thorough review of different SNPs, which were investigated for a correlation with the CRC risk, prognosis, and treatment response. We also analyzed the results from different meta-analyses and the possible reasons for reported contradictory findings, especially when different research groups investigated the same SNP in a gene for a particular miRNA. This illustrates the need for more case-control studies involving participants with different ethnic backgrounds. According to our review, three miRNAs-SNPs—miR-146a rs2910164, miR-27a rs895819 and miR-608 rs4919510—appear as promising prognostic, diagnostic and predictive biomarkers for CRC, respectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The meta-analysis for miR-196 included only two studies, with the following HR results (HR = 0.28, 95% CI: 0.15–0.52, p < 0.001; I 2 = 0%, p = 0.950, n = 197) [ 43 ]. In addition, there were three meta-analyses on miR-196a polymorphism as a risk of developing cancer [ 44 , 45 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

Potential Role of miR-196a and miR-196b as Prognostic Biomarkers of Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review, Meta-Analysis and Trial Sequential Analysis

Dioguardi

Cantore²,

Sovereto

et al. 2022

Life

View full text Add to dashboard Cite

The etiopathogenetic mechanisms involving tumor genesis, including alteration of cell proliferation, apoptosis, invasion, migration, and death, may lead to alterations in microRNAs (miR) expression. The hypothesis is that with the presence in the literature of recent studies conducted on miR-196a and miR-196b, it is possible to clearly determine, by aggregating the results, whether miR-196 upregulation in head and neck squamous cell carcinoma (HNSCC) tissues can represent a prognostic biomarker of survival through hazard ratio (HR) analysis. The systematic review was conducted following the indications of the PRISMA, and four electronic databases were used (Science Direct, SCOPUS, PubMed, and Cochrane Central), with the addition of gray literature. Combinations of keywords were used, such as miR-196, miR-196 AND HNSCC, microRNA AND HNSCC, LSCC AND miR-196, OSCC AND miR-196, OPSCC AND miR-196, HSCC AND miR-196. The meta-analysis and test sequential analysis were performed using RevMan 5.41 software and Stata 13 (StataCorp, College Station, TX, USA) with the implementation of the R 4.2 software. This search identified 1593 reports and, at the end of the selection, five articles were inserted. The results of the meta-analysis report an aggregate HR for overall survival (OS), between the highest and lowest miR-196 expression of 1.67, 95% CI: [1.16, 2.49]. In this meta-analysis, we found that the forest plot is in favor of higher OS in HNSCC patients, compared with the control, with low miR-196 expression, correlating this data with a favorable prognosis, which indicated the potential role of this miRNA in strengthening the therapy sensitiveness of the HNSCC patients. Consequently, the present systematic review places itself, together with other systematic reviews on this topic, in a key role to the finding of Phase 3 clinical trials studies, in search for a prognostic model of miR-196 for HNSCC. In conclusion, with the limitations of the systematic review, it can be argued that miRs of the miR-196 family could be independent prognostic biomarkers of survival for HNSCC.

show abstract

“…Specifically, the hsa-mir-146a residing rs2910164 (G to C variation) was linked to reduced HCC risk for the C allele while hsa-mir-34b/c rs4938723 (T to C variation) was associated with increased HCC risk. Furthermore, hsa-mir-196a-2 rs11614913 and hsa-mir-149 rs2292832 variations were all correlated with elevated HCC risk [319].…”

Section: Utilizing Non-coding Variants In Clinomicsmentioning

confidence: 92%

Non-Coding Variants in Cancer: Mechanistic Insights and Clinical Potential for Personalized Medicine

Lange

Begolli

Giakountis

2021

ncRNA

View full text Add to dashboard Cite

The cancer genome is characterized by extensive variability, in the form of Single Nucleotide Polymorphisms (SNPs) or structural variations such as Copy Number Alterations (CNAs) across wider genomic areas. At the molecular level, most SNPs and/or CNAs reside in non-coding sequences, ultimately affecting the regulation of oncogenes and/or tumor-suppressors in a cancer-specific manner. Notably, inherited non-coding variants can predispose for cancer decades prior to disease onset. Furthermore, accumulation of additional non-coding driver mutations during progression of the disease, gives rise to genomic instability, acting as the driving force of neoplastic development and malignant evolution. Therefore, detection and characterization of such mutations can improve risk assessment for healthy carriers and expand the diagnostic and therapeutic toolbox for the patient. This review focuses on functional variants that reside in transcribed or not transcribed non-coding regions of the cancer genome and presents a collection of appropriate state-of-the-art methodologies to study them.

show abstract

Comprehensive assessment for miRNA polymorphisms in hepatocellular cancer risk: a systematic review and meta-analysis

Cited by 9 publications

References 82 publications

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis

Potential Role of miR-196a and miR-196b as Prognostic Biomarkers of Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review, Meta-Analysis and Trial Sequential Analysis

Non-Coding Variants in Cancer: Mechanistic Insights and Clinical Potential for Personalized Medicine

Contact Info

Product

Resources

About